Elevated Liver Aminotransferases Level and COVID-19 Prognosis in Hospitalized Patients: A Prospective Study from Iran

Dinevari, Masood Faghih; Somi, Mohammad Hossein; Majd, Elham Sadeghi; Fattahzadeh, Afshin; Nikniaz, Zeinab

doi:10.34172/mejdd.2022.257

Cited by 3 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the initial examination, 6462 studies were obtained, which were screened and evaluated layer by layer according to inclusion and exclusion criteria, and 49 studies were finally included, most of which were retrospective studies, from 10 countries, with a total of 23,611 COVID-19 patients, including 9357 cases complicated with liver injury. [7–55] The flow chart of literature screening is shown in Figure 1. The basic characteristics of the included literature are shown in Table 1.…”

Section: Resultsmentioning

confidence: 99%

Meta-analysis of liver injury in patients with COVID-19

Fan

Jin

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: The coronavirus disease 2019 (COVID-19) is a major public health problem threatening human health. It can lead to multiple system complications, among which liver damage is also a common complication of COVID-19. The pathogenesis of liver injury is complex and involves the interaction of multiple factors. This study aims to investigate the incidence and risk factors of liver injury in COVID-19 patients and analyze the impact of liver injury on clinical prognosis of patients, so as to provide corresponding basis for clinical diagnosis and treatment. Methods: PubMed and Cochrane Library were searched in computer to collect original studies on liver injury cases, laboratory indicators and clinical outcomes in COVID-19 patients. Articles were screened according to inclusion and exclusion criteria, and data were meta-analyzed using Stata12.0 software. Results: A total of 49 studies, including 23,611 patients with COVID-19, had a prevalence of liver injury of 39.63%. Subgroup analysis found that patients in the Americas had the highest incidence of liver injury at 43.7% and lowest in Africa (25.99%). The vast majority of liver injury is manifested by aminotransferase or bilirubin levels greater than 1 times the upper limit of normal (49.16%). The older the age, the male, the associated chronic liver disease, and the higher the levels of white blood cells, neutrophils, and C-reactive protein, the higher the risk of liver injury. The use of hormones, hydroxychloroquine, and tocilizumab increases the risk of liver injury. Patients with concurrent liver injury have longer hospital stays, are more likely to progress to severe cases, and have a higher risk of death than patients without liver injury. Conclusion: The incidence of liver injury in COVID-19 patients was high, affected by age, gender, chronic liver disease, inflammatory state and medication, and patients with liver injury were hospitalized longer and were more likely to have a poor prognosis. Therefore, clinical attention should be paid to early intervention.

show abstract

Section: Resultsmentioning

confidence: 99%

Meta-analysis of liver injury in patients with COVID-19

Fan

Jin

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…The presence of preexisting comorbidities was one of the main reasons for higher mortality in these patients. [3][4][5][6][7] Instead, the association between medication use and the risk of mortality in COVID-19 patients was investigated in various studies. For example, some studies suggested that since antihypertensive drugs increase Angiotensinconverting enzyme 2 (ACE2) expression, [8][9][10][11] they could worsen the prognosis of COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Association of Cardiovascular Disease, Respiratory Diseases, and Diabetes Treatment With COVID-19 Mortality in Hospitalized Patients

Nikniaz,

Faghih Dinevari,

Mokhtari

2023

Int J Drug Res Clin

View full text Add to dashboard Cite

Background: The prevalence of the coronavirus disease 2019 (COVID-19) in patients with preexisting non-communicable disease was high, and there was a question regarding the effect of the usage of medications on COVID-19 outcomes in these patients. Therefore, this study investigated the outcome of patients with different cardiovascular diseases (CVDs), respiratory diseases, and diabetes drug use. Methods: In this analytical longitudinal study, information was collected on clinical laboratory data, COVID-19 severity, comorbidities, and drug use. The follow-up time was from enrollment to discharge or death. Results: A total of 1046 hospitalized patients with COVID-19 participated in this analytical longitudinal study. The most commonly used drugs were CVD drugs (39.4%) and diabetes drugs (19.7%). The frequency of drug use was statistically similar between survivors and non-survivors except for diabetic drug use which was significantly higher in non-survivors (P=0.04). Patients who used the diabetic drugs were more likely to die (odds ratio [OR]: 1.41, 95% CI: 1.008-1.97). Moreover, the association was not significant after adjusting to confounding factors, and there was no significant association between other drug use and death in patients with COVID-19. Conclusion: The result of the present study showed that antihypertensive treatments, antidiabetic, and respiratory disease drugs were not associated with higher deaths in hospitalized patients with COVID-19.

show abstract

COVID-19, Possible Hepatic Pathways and Alcohol Abuse—What Do We Know up to 2023?

Michalak,

Lach,

Szczygieł

et al. 2024

IJMS

View full text Add to dashboard Cite

The pandemic period due to coronavirus disease 2019 (COVID-19) revolutionized all possible areas of global health. Significant consequences were also related to diverse extrapulmonary manifestations of this pathology. The liver was found to be a relatively common organ, beyond the respiratory tract, affected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Multiple studies revealed the essential role of chronic liver disease (CLD) in the general outcome of coronavirus infection. Present concerns in this field are related to the direct hepatic consequences caused by COVID-19 and pre-existing liver disorders as risk factors for the severe course of the infection. Which mechanism has a key role in this phenomenon—previously existing hepatic disorder or acute liver failure due to SARS-CoV-2—is still not fully clarified. Alcoholic liver disease (ALD) constitutes another not fully elucidated context of coronavirus infection. Should the toxic effects of ethanol or already developed liver cirrhosis and its consequences be perceived as a causative or triggering factor of hepatic impairment in COVID-19 patients? In the face of these discrepancies, we decided to summarize the role of the liver in the whole picture of coronavirus infection, paying special attention to ALD and focusing on the pathological pathways related to COVID-19, ethanol toxicity and liver cirrhosis.

show abstract

Elevated Liver Aminotransferases Level and COVID-19 Prognosis in Hospitalized Patients: A Prospective Study from Iran

Cited by 3 publications

References 22 publications

Meta-analysis of liver injury in patients with COVID-19

Meta-analysis of liver injury in patients with COVID-19

Association of Cardiovascular Disease, Respiratory Diseases, and Diabetes Treatment With COVID-19 Mortality in Hospitalized Patients

COVID-19, Possible Hepatic Pathways and Alcohol Abuse—What Do We Know up to 2023?

Contact Info

Product

Resources

About